---
title: "AE_PAZOPANIB"
date: "2023-12-01 17:01:03"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[adverse event-of-snippets]]

# AE_PAZOPANIB

AEs such as hypertension (50%) within 1st 18 weeks, diarrhea, n/v, abdominal pain, lipase elevated (30%), risk of GI situlas and/or perforations, fatigue, depigmentation, bleeding complications with hematuria, epistaxis, and hemoptysis, increased risk of arterial thrombolic envents (MI, angina, TIA and stroke), proteinuria (8%), and etc

### Siblings

- [[AE_ABVD]]
- [[AE_ACT]]
- [[AE_ALECTINIB]]
- [[AE_ALIMTA]]
- [[AE_ALPELISIB]]
- [[AE_BENDAMUSTINE]]
- [[AE_CCRT]]
- [[AE_CDK46]]
- [[AE_CRIZOINIB]]
- [[AE_DABRAFENIB]]
- [[AE_ENHERTU]]
- [[AE_ERIBULIN]]
- [[AE_FOLFOX]]
- [[AE_GLIVEC]]
- [[AE_HERCEPTIN]]
- [[AE_LANREOTIDE]]
- [[AE_LAPATINIB]]
- [[AE_LAR]]
- [[AE_LETROZOLE]]
- [[AE_OLAPARIB]]
- [[AE_OSIMERTINIB]]
- [[AE_PAZOPANIB]]
- [[AE_PEMIGATINIB]]
- [[AE_PERTUZUMAB]]
- [[AE_RAMUCIRUMAB]]
- [[AE_RECTAL]]
- [[AE_REGORAFENIB]]
- [[AE_SORAFENIB]]
- [[AE_SUNITINIB]]
- [[AE_TAS102]]
- [[AE_TAXOTERECDDP]]
- [[AE_TOPOTECAN]]
- [[AE_UFT]]
- [[AE_VEMURAFENIB]]
- [[AE_VINORELBINE]]
- [[AE_XELOX]]

